PHDS and the Irvine Pharmaceutical Services, Inc. (IPS) signed a formal agreement on July 26 in Beijing , declaring the establishment of a joint venture Dr.K-PHDS. This ground-breaking enterprise is devoted to bridge the gap between the East and the West pharmaceutical industry. Equipped with a whole system of comprehensive services in pharmaceutical research and development, Dr.K-PHDS provides high-end services to the global pharmaceutical clients.

IPS is a leading U.S. contract research laboratory for analysis and test fully complying cGMP. IPS provides analytical chemistry and microbiological research services for pharmaceutical, biotechnology and medical device enterprises. It focuses on regular quality control final testing analytical support services in drug development (method development and validation, stability storage and testing) and microbiological support.

PHDS is a global CRO equipped with an excellent expert and CRA team. PHDS specializes in clinical trial management and has a portfolio of successful cases.

Combining the strengths of the two organizations, the transnational Dr.K-PHDS’ core business is international multi-center clinical trial and clinical development of new drug and import drug. With IPS’ pharmacological analysis capabilities, an all-encompassing drug development service system will be formed. The core competitiveness of Dr.K-PHDS is powerful human and social resources and the advantages of the unique transnational alliance.